247 related articles for article (PubMed ID: 35638227)
1. Are we ready for long-acting? A feasibility evaluation of long-acting cabotegravir-rilpivirine in clinical practice.
Borghetti A; Farinacci D; Ciccullo A; Dusina A; Moschese D; Iannone V; D'Angelillo A; Lombardi F; Donne VD; Massaroni V; Visconti E; Tamburrini E; Di Giambenedetto S
J Med Virol; 2022 Oct; 94(10):4970-4974. PubMed ID: 35638227
[TBL] [Abstract][Full Text] [Related]
2. Favorable Virological Outcome, Characteristics of Injection Site Reactions, Decrease in Renal Function Biomarkers in Asian People with HIV Receiving Long-Acting Cabotegravir Plus Rilpivirine.
Adachi E; Saito M; Otani A; Koga M; Yotsuyanagi H
AIDS Res Hum Retroviruses; 2024 Apr; 40(4):216-222. PubMed ID: 38164081
[TBL] [Abstract][Full Text] [Related]
3. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
Margolis DA; Gonzalez-Garcia J; Stellbrink HJ; Eron JJ; Yazdanpanah Y; Podzamczer D; Lutz T; Angel JB; Richmond GJ; Clotet B; Gutierrez F; Sloan L; Clair MS; Murray M; Ford SL; Mrus J; Patel P; Crauwels H; Griffith SK; Sutton KC; Dorey D; Smith KY; Williams PE; Spreen WR
Lancet; 2017 Sep; 390(10101):1499-1510. PubMed ID: 28750935
[TBL] [Abstract][Full Text] [Related]
4. Frequency of genotypic factors possibly associated with cabotegravir/rilpivirine failure in antiretroviral treatment-naïve and -experienced HIV-1- infected population.
Scheibe K; Urbańska A; Serwin K; Parczewski M
Infect Genet Evol; 2022 Oct; 104():105358. PubMed ID: 36057423
[TBL] [Abstract][Full Text] [Related]
5. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
[TBL] [Abstract][Full Text] [Related]
6. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.
Orkin C; Bernal Morell E; Tan DHS; Katner H; Stellbrink HJ; Belonosova E; DeMoor R; Griffith S; Thiagarajah S; Van Solingen-Ristea R; Ford SL; Crauwels H; Patel P; Cutrell A; Smith KY; Vandermeulen K; Birmingham E; St Clair M; Spreen WR; D'Amico R
Lancet HIV; 2021 Nov; 8(11):e668-e678. PubMed ID: 34656207
[TBL] [Abstract][Full Text] [Related]
7. Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study.
Lowenthal ED; Chapman J; Ohrenschall R; Calabrese K; Baltrusaitis K; Heckman B; Yin DE; Agwu AL; Harrington C; Van Solingen-Ristea RM; McCoig CC; Adeyeye A; Kneebone J; Chounta V; Smith-Anderson C; Camacho-Gonzalez A; D'Angelo J; Bearden A; Crauwels H; Huang J; Buisson S; Milligan R; Ward S; Bolton-Moore C; Gaur AH; ;
Lancet HIV; 2024 Apr; 11(4):e222-e232. PubMed ID: 38538161
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patients.
Charpentier C; Storto A; Soulié C; Ferré VM; Wirden M; Joly V; Lambert-Niclot S; Palich R; Morand-Joubert L; Landman R; Lacombe K; Katlama C; Ghosn J; Marcelin AG; Calvez V; Descamps D
J Antimicrob Chemother; 2021 Oct; 76(11):2983-2987. PubMed ID: 34015097
[TBL] [Abstract][Full Text] [Related]
9. Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.
Gaur AH; Capparelli EV; Calabrese K; Baltrusaitis K; Marzinke MA; McCoig C; Van Solingen-Ristea RM; Mathiba SR; Adeyeye A; Moye JH; Heckman B; Lowenthal ED; Ward S; Milligan R; Samson P; Best BM; Harrington CM; Ford SL; Huang J; Crauwels H; Vandermeulen K; Agwu AL; Smith-Anderson C; Camacho-Gonzalez A; Ounchanum P; Kneebone JL; Townley E; Bolton Moore C; ;
Lancet HIV; 2024 Apr; 11(4):e211-e221. PubMed ID: 38538160
[TBL] [Abstract][Full Text] [Related]
10. Contribution of cabotegravir + rilpivirine long-acting for the treatment of HIV-1 infection.
Calleja-Hernández MÁ; Martinez-Sesmero JM; Vallejo-Aparicio LA; Hernández-Novoa B; Badia X
Farm Hosp; 2022 Jul; 46(4):208-214. PubMed ID: 36183218
[TBL] [Abstract][Full Text] [Related]
11. Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy.
D'Amico R; Cenoz Gomis S; Moodley R; Van Solingen-Ristea R; Baugh B; Van Landuyt E; Van Eygen V; Min S; Cutrell A; Foster C; Chilton D; Allard SD; Ruiter A
HIV Med; 2023 Feb; 24(2):202-211. PubMed ID: 35945163
[TBL] [Abstract][Full Text] [Related]
12. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Overton ET; Richmond G; Rizzardini G; Jaeger H; Orrell C; Nagimova F; Bredeek F; García Deltoro M; Swindells S; Andrade-Villanueva JF; Wong A; Khuong-Josses MA; Van Solingen-Ristea R; van Eygen V; Crauwels H; Ford S; Talarico C; Benn P; Wang Y; Hudson KJ; Chounta V; Cutrell A; Patel P; Shaefer M; Margolis DA; Smith KY; Vanveggel S; Spreen W
Lancet; 2021 Dec; 396(10267):1994-2005. PubMed ID: 33308425
[TBL] [Abstract][Full Text] [Related]
13. Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the
Jeffrey JL; St Clair M; Wang P; Wang C; Li Z; Beloor J; Talarico C; Fridell R; Krystal M; White CT; Griffith S; D'Amico R; Smith K; Van Eygen V; Vingerhoets J; Vandermeulen K; Spreen W; van Lunzen J
Antimicrob Agents Chemother; 2022 Mar; 66(3):e0170221. PubMed ID: 34978890
[TBL] [Abstract][Full Text] [Related]
14. Monthly injectable cabotegravir/rilpivirine to manage HIV infection in adults.
Blackwell CW; López Castillo H
J Am Assoc Nurse Pract; 2022 Jul; 34(7):918-923. PubMed ID: 35580282
[TBL] [Abstract][Full Text] [Related]
15. Long-acting Injectable Cabotegravir/Rilpivirine Effective in a Small Patient Cohort With Virologic Failure on Oral Antiretroviral Therapy.
Brock JB; Herrington P; Hickman M; Hickman A
Clin Infect Dis; 2024 Jan; 78(1):122-124. PubMed ID: 37740255
[TBL] [Abstract][Full Text] [Related]
16. Long-acting combination of cabotegravir plus rilpivirine: A picture of potential eligible and ineligible HIV-positive individuals from the Italian ARCA cohort.
Cervo A; Russo A; Di Carlo D; De Vito A; Fabeni L; D'Anna S; Duca L; Colpani A; Fois M; Zauli B; Mancarella G; Carraro A; Bezenchek A; Cozzi-Lepri A; Santoro MM;
J Glob Antimicrob Resist; 2023 Sep; 34():141-144. PubMed ID: 37453495
[TBL] [Abstract][Full Text] [Related]
17. Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV.
Taki E; Soleimani F; Asadi A; Ghahramanpour H; Namvar A; Heidary M
Expert Rev Anti Infect Ther; 2022 Aug; 20(8):1135-1147. PubMed ID: 35596583
[TBL] [Abstract][Full Text] [Related]
18. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
Orkin C; Oka S; Philibert P; Brinson C; Bassa A; Gusev D; Degen O; García JG; Morell EB; Tan DHS; D'Amico R; Dorey D; Griffith S; Thiagarajah S; St Clair M; Van Solingen-Ristea R; Crauwels H; Ford SL; Patel P; Chounta V; Vanveggel S; Cutrell A; Van Eygen V; Vandermeulen K; Margolis DA; Smith KY; Spreen WR
Lancet HIV; 2021 Apr; 8(4):e185-e196. PubMed ID: 33794181
[TBL] [Abstract][Full Text] [Related]
19. Archived rilpivirine-associated resistance mutations among ART-naive and virologically suppressed people living with HIV-1 subtype C in Botswana: implications for cabotegravir/rilpivirine use.
Maruapula D; Moraka NO; Bareng OT; Mokgethi PT; Choga WT; Seatla KK; Kelentse N; Koofhethille CK; Zuze BJL; Gaolathe T; Pretorius-Holme M; Makhema J; Novitsky V; Shapiro R; Moyo S; Lockman S; Gaseitsiwe S
J Antimicrob Chemother; 2023 Oct; 78(10):2489-2495. PubMed ID: 37585352
[TBL] [Abstract][Full Text] [Related]
20. Perspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation-effectiveness study (CUSTOMIZE).
Czarnogorski M; Garris CP; Dalessandro M; D'Amico R; Nwafor T; Williams W; Merrill D; Wang Y; Stassek L; Wohlfeiler MB; Sinclair GI; Mena LA; Thedinger B; Flamm JA; Benson P; Spreen WR
J Int AIDS Soc; 2022 Sep; 25(9):e26003. PubMed ID: 36094142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]